ProCE Banner Events

Share

Challenging Treatment Paradigms in HER2-Low and HER2-Ultralow MBC: Experts Examine The Evidence to Guide Individualized Clinical Decisions

Live satellite symposium with a panel of experts discussing the current landscape for patients with HER2-ultralow to HER2-positive mBC, including new and emerging treatment options and expert guidance to help inform treatment decisions and therapy sequencing.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Who Should Attend

This activity has been designed to meet the educational needs of oncologists and other healthcare professionals caring for patients with mBC.

Time and location

Friday, May 30, 2025

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Agenda

Registration & Dinner: 6:30 PM - 7:00 PM CT

Symposium: 7:00 PM - 8:30 PM CT

 

Welcome, Baseline Assessment, Introduction  

I. HER2 Assessment and Testing in 2025: What HCPs Need to Know   

  • Brief overview of HER2 alterations in mBC
    • New “HER2 ultralow” status and expanding eligibility HER2-targeted agents in mBC
    • Diagnostic workup for HER2-low/ultralow mBC population
    • Circumstances for rebiopsy in mBC
      • Implications of changing HER2 status on treatment strategies
  • HER2 testing/scoring

II. Clinical Application: Selecting Treatment for HR+/HER2- mBC Following Multiple Lines of Endocrine Therapy

  • Selection of therapy in patients with HR+/HER2-ultralow/low mBC who have received endocrine-based therapy and at least 2 additional systemic therapies
  • Selection of therapy in patients with HR+/HER2-ultralow/low mBC (IHC 0, IHC 1+, or IHC 2+/ISH-) mBC who progress <6 months after 1L ET + CDK4/6i or <24 months of adjuvant ET

III. Maximizing Safety and Efficacy of ADCs

  • How do we differentiate between common and challenging  treatment-related AEs, and how do these distinctions affect patient care?
    • Proactive AE management strategies and how can these strategies be tailored to individual patient needs?
  • Strategies to monitor for symptoms and ensuring prompt identification of significant nausea and vomiting?
  • NCCN and ASCO guidelines for ADC AE management
  • Identifying key differences between disease-related and treatment-related AE symptoms

IV. Clinical Application of Recent Developments: What’s Next? And a Look to the Future in HER2-Low mBC  

  • Panel discussion
  • Key program takeaways

Section 5: Question and Answer Session

Location

Venue Name

Hilton Chicago

Address

Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with breast cancer. 

Target Audience
This activity has been designed to meet the educational needs of oncologists and other healthcare professionals caring for patients with mBC.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Implement best practices to identify patients with MBC who may benefit from HER2-targeted therapy through optimal assessment of HER2 status and streamline communication of results.
  • Evaluate the latest clinical data and guidelines for the treatment of HER2-low and HER2-ultralow MBC following progression on endocrine therapy
  • Explain emerging data and educate colleagues and counsel patients regarding ongoing trial opportunities in HER2-low and HER2-ultralow MBC
  • Develop protocols for regular patient monitoring during and after ADC treatment to detect and manage adverse events promptly.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.